NCT02092207View on ClinicalTrials.gov

Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Dry Eye Syndrome
Interventions
DRUG

KL7016 900mg

oral administration, 150mg 3tab, bid

DRUG

KL7016 600mg

oral administration, 150mg 3tab, bid

DRUG

Placebo

oral administration, 150mg 3tab, bid

Trial Locations (9)

137-701

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

135-720

Gangnam Severance Hospital, Seoul

463-707

Seoul National University Bundang Hospital, Gyeonggi-do

152-703

Korea University Guro Hospital, Seoul

135-710

Samsung Medical Center, Seoul

501-757

Chonnam National University Hospital, Gwangju

143-729

Konkuk University Medical Center, Seoul

138-736

ASAN Medical Center, Seoul

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT02092207 - Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome | Biotech Hunter | Biotech Hunter